Clinical Trials Logo

Metastatic Pancreatic Cancer clinical trials

View clinical trials related to Metastatic Pancreatic Cancer.

Filter by:

NCT ID: NCT00326911 Terminated - Clinical trials for Metastatic Pancreatic Cancer

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

Start date: May 2006
Phase: Phase 2
Study type: Interventional

Eligible patients with metastatic pancreatic cancer will be treated with dual agent monoclonal antibody consisting of cetuximab and bevacizumab alone or in combination with gemcitabine

NCT ID: NCT00245362 Completed - Clinical trials for Metastatic Pancreatic Cancer

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

Start date: June 2002
Phase: Phase 2
Study type: Interventional

To evaluate the safety and effectiveness of CG8020 and CG2505.

NCT ID: NCT00222469 Completed - Clinical trials for Metastatic Pancreatic Cancer

Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer

Start date: August 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival. In addition, the study will find out what side effects patients may have by taking bevacizumab, oxaliplatin, and gemcitabine together.